Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Initial alpha-fetoprotein response predicts survival, recurrence after radiofrequency ablation

28 Feb 2018

Measurement of serial alpha-fetoprotein (AFP) levels to evaluate biological response may help predict overall survival and intrahepatic remote recurrence after radiofrequency ablation (RFA), suggests a recent study.

“Therefore, an initial AFP response may aid in determining the need of closer follow-up as a therapeutic response indicator of RFA,” according to the investigators.

Of the 255 patients included in the analysis, 156 (61.2 percent) developed intrahepatic recurrence. Radiologic progression occurred in 54.8 percent (86/157) and 71.4 percent (70/98) of the AFP responders and nonresponders, respectively.

Multivariate analysis revealed that a history of previous treatment (hazard ratio [HR] for percutaneous ethanol injection vs none, 2.037; p=0.015; HR for transarterial chemoembolization vs none, 2.642; p<0.001) and an initial AFP nonresponse (HR, 1.899; p<0.001) independently predicted accelerated progression following RFA.

Furthermore, overall survival was significantly unfavourable (HR, 3.581; p<0.001) and the risk of intrahepatic remote recurrence was greater (HR, 5.385; p<0.001) among patients who had a history of previous treatment and did not achieve an initial AFP response compared with those with an initial AFP response and no history of previous treatment.

The investigators prospectively enrolled naïve as well as previously treated patients with solitary hepatitis B virus-related hepatocellular carcinoma <5 cm in this study to identify prognostic factors included AFP for overall survival and intrahepatic recurrence after RFA.

An initial AFP response was defined as a ≥50-percent reduction from baseline to 1 month after RFA. Tumour responses were assessed using the modified response evaluation criteria in solid tumours.

“RFA is effective for early-stage hepatocellular carcinoma but recurrence is problem,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.